FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323535687> ?p ?o ?g. }

• W4323535687 endingPage "3296" @default.
• W4323535687 startingPage "3284" @default.
• W4323535687 abstract "Abstract Acute myeloid leukemia (AML) can be treated with either high- or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response quality. We hypothesized that treatment (Rx) intensity may not be a key predictor of outcomes, assuming that an optimal response to therapy is achieved. We performed a single-center retrospective study including 635 patients with newly diagnosed AML responding to either intensive cytarabine/anthracycline-based chemotherapy (IA; n = 385) or low-intensity venetoclax-based regimens (LOW + VEN; n = 250) and who had adequate flow cytometry–based MRD testing performed at the time of best response. The median overall survival (OS) was 50.2, 18.2, 13.6, and 8.1 months for the IA MRD−, LOW + VEN MRD−, IA MRD+, and LOW + VEN MRD+ cohorts, respectively. The 2-year cumulative incidence of relapse (CIR) was 41.1%, 33.5%, 64.2%, and 59.9% for the IA MRD−, LOW + VEN MRD−, IA MRD+, and LOW + VEN MRD+ cohorts, respectively. The CIR was similar between patients within MRD categories irrespective of the treatment regimen received. The IA cohort was enriched for younger patients and favorable AML cytogenetic/molecular categories. Using multivariate analysis, age, best response (complete remission [CR]/CR with incomplete hematologic recovery/morphologic leukemia-free state), MRD status, and European LeukemiaNet (ELN) 2017 risk remained significantly associated with OS, whereas best response, MRD status, and ELN 2017 risk were significantly associated with CIR. Treatment intensity was not significantly associated with either OS or CIR. Achievement of MRD− CR should be the key objective of AML therapy in both high- and low-intensity treatment regimens." @default.
• W4323535687 created "2023-03-09" @default.
• W4323535687 creator A5000750846 @default.
• W4323535687 creator A5010663972 @default.
• W4323535687 creator A5016368595 @default.
• W4323535687 creator A5018403822 @default.
• W4323535687 creator A5019126236 @default.
• W4323535687 creator A5020340537 @default.
• W4323535687 creator A5028591457 @default.
• W4323535687 creator A5029750735 @default.
• W4323535687 creator A5035605515 @default.
• W4323535687 creator A5036349678 @default.
• W4323535687 creator A5046597133 @default.
• W4323535687 creator A5049385583 @default.
• W4323535687 creator A5050041791 @default.
• W4323535687 creator A5050914134 @default.
• W4323535687 creator A5056317446 @default.
• W4323535687 creator A5057822243 @default.
• W4323535687 creator A5060548911 @default.
• W4323535687 creator A5061026876 @default.
• W4323535687 creator A5065499641 @default.
• W4323535687 creator A5069176297 @default.
• W4323535687 creator A5070065917 @default.
• W4323535687 creator A5075581944 @default.
• W4323535687 creator A5079262854 @default.
• W4323535687 creator A5084379902 @default.
• W4323535687 creator A5089295627 @default.
• W4323535687 creator A5089428686 @default.
• W4323535687 creator A5091492845 @default.
• W4323535687 date "2023-07-03" @default.
• W4323535687 modified "2023-10-15" @default.
• W4323535687 title "Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity" @default.
• W4323535687 cites W1600365609 @default.
• W4323535687 cites W16058864 @default.
• W4323535687 cites W1832802185 @default.
• W4323535687 cites W1973617793 @default.
• W4323535687 cites W1981449355 @default.
• W4323535687 cites W2013923593 @default.
• W4323535687 cites W2034058960 @default.
• W4323535687 cites W203809443 @default.
• W4323535687 cites W2038981426 @default.
• W4323535687 cites W2079581614 @default.
• W4323535687 cites W2106084333 @default.
• W4323535687 cites W2128541003 @default.
• W4323535687 cites W2161938647 @default.
• W4323535687 cites W2559537906 @default.
• W4323535687 cites W2751152093 @default.
• W4323535687 cites W2760499085 @default.
• W4323535687 cites W2807921412 @default.
• W4323535687 cites W2906776252 @default.
• W4323535687 cites W3013447738 @default.
• W4323535687 cites W3048827006 @default.
• W4323535687 cites W3092079205 @default.
• W4323535687 cites W3094967368 @default.
• W4323535687 cites W3096161702 @default.
• W4323535687 cites W3096212403 @default.
• W4323535687 cites W3107627007 @default.
• W4323535687 cites W3131323362 @default.
• W4323535687 cites W3164441110 @default.
• W4323535687 cites W3202266999 @default.
• W4323535687 cites W3209416216 @default.
• W4323535687 cites W3211287861 @default.
• W4323535687 cites W4200103238 @default.
• W4323535687 cites W4223909493 @default.
• W4323535687 cites W4242752547 @default.
• W4323535687 cites W4282925423 @default.
• W4323535687 cites W4283783771 @default.
• W4323535687 cites W4284884567 @default.
• W4323535687 cites W4285719527 @default.
• W4323535687 cites W4306796751 @default.
• W4323535687 cites W4310104765 @default.
• W4323535687 doi "https://doi.org/10.1182/bloodadvances.2022009391" @default.
• W4323535687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36884300" @default.
• W4323535687 hasPublicationYear "2023" @default.
• W4323535687 type Work @default.
• W4323535687 citedByCount "1" @default.
• W4323535687 countsByYear W43235356872023 @default.
• W4323535687 crossrefType "journal-article" @default.
• W4323535687 hasAuthorship W4323535687A5000750846 @default.
• W4323535687 hasAuthorship W4323535687A5010663972 @default.
• W4323535687 hasAuthorship W4323535687A5016368595 @default.
• W4323535687 hasAuthorship W4323535687A5018403822 @default.
• W4323535687 hasAuthorship W4323535687A5019126236 @default.
• W4323535687 hasAuthorship W4323535687A5020340537 @default.
• W4323535687 hasAuthorship W4323535687A5028591457 @default.
• W4323535687 hasAuthorship W4323535687A5029750735 @default.
• W4323535687 hasAuthorship W4323535687A5035605515 @default.
• W4323535687 hasAuthorship W4323535687A5036349678 @default.
• W4323535687 hasAuthorship W4323535687A5046597133 @default.
• W4323535687 hasAuthorship W4323535687A5049385583 @default.
• W4323535687 hasAuthorship W4323535687A5050041791 @default.
• W4323535687 hasAuthorship W4323535687A5050914134 @default.
• W4323535687 hasAuthorship W4323535687A5056317446 @default.
• W4323535687 hasAuthorship W4323535687A5057822243 @default.
• W4323535687 hasAuthorship W4323535687A5060548911 @default.
• W4323535687 hasAuthorship W4323535687A5061026876 @default.
• W4323535687 hasAuthorship W4323535687A5065499641 @default.
• W4323535687 hasAuthorship W4323535687A5069176297 @default.

• next